Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox approved in Finland

Apr 27, 2018Cathy WilsonNews

24 April 2018

ASX Announcement

Penthrox approved in Finland

Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Finland.

 

For the full release, please refer to the following link: Penthrox approved in Finland

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • FY23 Half Year ASX Announcement

    24 February 2023 ASX Anno...

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter